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Abstract
Objective To determine whether detection of invasive cervical cancer
by screening results in better prognosis or merely increases the lead
time until death.
Design Nationwide population based cohort study.
Setting Sweden.
Participants All 1230 women with cervical cancer diagnosed during
1999-2001 in Sweden prospectively followed up for an average of 8.5
years.
Main outcome measures Cure proportions and five year relative survival
ratios, stratified by screening history, mode of detection, age,
histopathological type, and FIGO (International Federation of Gynecology
and Obstetrics) stage.
Results In the screening ages, the cure proportion for women with
screen detected invasive cancer was 92% (95% confidence interval 75%
to 98%) and for symptomatic women was 66% (62% to 70%), a
statistically significant difference in cure of 26% (16% to 36%). Among
symptomatic women, the cure proportion was significantly higher for
those who had been screened according to recommendations (interval
cancers) than among those overdue for screening: difference in cure
14% (95% confidence interval 6% to 23%). Cure proportions were similar
for all histopathological types except small cell carcinomas and were
closely related to FIGO stage. A significantly higher cure proportion for
screen detected cancers remained after adjustment for stage at diagnosis
(difference 15%, 7% to 22%).
Conclusions Screening is associated with improved cure of cervical
cancer. Confounding cannot be ruled out, but the effect was not
attributable to lead time bias and was larger than what is reflected by
down-staging. Evaluations of screening programmes should consider
the assessment of cure proportions.
Introduction
The rationale of cervical screening is to reduce the incidence
of cancer by the detection and treatment of precursors.
1 2 A
secondary aim is the early detection of invasive disease, which
might improve the prognosis thereby also reducing mortality
from the disease. Prognosis may depend on age, FIGO
(International Federation of Gynecology and Obstetrics) stage,
histopathologicaltype,screeninghistory,andmodeofdetection.
3
Thuscancersmaybedetectedonthebasisofeitheranabnormal
screening test result or symptoms, and the women may also
have been screened previously according to recommendations
or not. The Swedish cervical screening programme carried out
a nationwide audit of the screening history of all cases in the
countryandfoundthatinadditiontopreventingcervicalcancer,
regular screening also detected invasive cervical cancers at
earlier stages. In the nationwide Swedish audit
1 around 50% of
women who were not screened according to recommendations
weredetectedatFIGOstageIIorhigher,whereasamongwomen
participating in the screening programme most were at stages
IA or IB (30% and 52%, respectively). For screen detected
cancersthedrifttowardsdetectionatearlystageswasevenmore
apparent (47% of cancers were detected at stage IA and 46% at
stage IB).
However, the early detection of asymptomatic cancers is
intuitively but not necessarily beneficial,
4-6 as lead time and
length biases can distort the apparent benefit of screening
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Research
RESEARCHprogrammes.
7 8 Randomised controlled trials are not feasible
fortheevaluationofestablishedcervicalscreeningprogrammes,
whichiswhytheonlyalternativeiswelldesignedobservational
studies.
9 In an extension of the nationwide Swedish audit, we
investigated if, and to what extent, participation in cervical
screening according to guidelines and/or screen detection of
invasive cancer is reflected in improved cure of disease by
utilising recently developed statistical methods for estimating
the cured proportion of women with cervical cancer.
10 11
Methods
The organised Swedish cervical screening programme issues
invitationsthreeyearsafterthelatestsmeartestforwomenaged
23-50 and every five years for women aged 51-60. Invitations
to screening are issued by regional offices to all women in the
population register who have not been screened according to
recommendations.
12-14 The cytology databases used to assess
screening history include all smear tests taken, not just the
organised ones. The design of the nationwide audit of cervical
screening in Sweden has been described previously.
1 In the
present prospective cohort study we linked all women with
cervical cancer in Sweden diagnosed during 1999-2001 to the
national Swedish causes of death register, with follow-up to 31
December 2006. Death from cervical cancer or unspecified
uterine cancer was considered cause specific mortality.
15 To
ascertain the date of death from any cause until 31 December
2008, we linked all cases to the Swedish population register.
We analysed separately those women with cancer diagnosed at
screening ages 23-65 (including one woman with a diagnosis
at age 21) and those with a diagnosis more than five years
beyond the last invitation to screening (≥66 years). Screen
detected cancers were defined as those in women with an
abnormalsmeartestresultrecorded1-6monthsbeforediagnosis.
We classified the remaining women as symptomatic.
1 Smear
tests taken less than one month before diagnosis were not
considered as they might be part of the diagnostic process of a
symptomatic invasive cancer (fig 1⇓).
We divided the women with symptomatic cancer into
symptomatic interval cases if the cancer was diagnosed more
thansixmonthsafterthesmeartestbutwithintherecommended
screening interval of 3.5 years in women under the age of 54,
or within 5.5 years before diagnosis in women over that age.
Symptomaticoverdue,ornotscreened,comprisedwomenwhose
screening test was more than half a year overdue according to
screeningguidelines,andincludedwomenwithoutanyprevious
smear test. We divided the women with screen detected cancer,
having a smear test done 1-6 months before diagnosis, into
women who also had a smear test taken within the preceding
recommended interval (screen detected interval cancers) and
those whose screening was overdue or who had no recorded
smear test (screen detected, overdue or not screened).
FIGO stage is considered a good predictor of survival.
16-18 The
classification used in this study—IA, microinvasive; IB,
localised; and II or higher, advanced—reflect distinct levels of
treatment, consequences for fertility, complications, and costs.
Statistical analysis
We calculated relative survival ratios as the overall (all cause)
survival in the cohort over the expected survival in the general
female population, comparable with the women diagnosed as
having cancer according to age and calendar year. Relative
survival estimates mortality, associated with a diagnosis of a
particular disease, without the need for information on cause of
death.
19
Statisticalcureisdefinedasthepointwheretherelativesurvival
curve reaches a plateau, and this occurs when the women who
are still alive no longer experience any excess mortality
compared with the general female population. These women
are considered statistically cured as they experience the same
mortality as women of the same age without cancer. The level
at which the relative survival curve reaches a plateau is named
the cure proportion.
10 The concept of “statistical cure” applies
at a grouped level and is distinct from “medical cure” at an
individuallevel,asitisdifficulttodeterminewithanycertainty
that someone has been medically cured.
The statistical model for cure used in this paper—the mixture
cure model
10—assumes that a proportion of patients will be
cured(experiencethesamemortalityasthegeneralpopulation)
whereas the remaining (1−proportion) of patients will continue
to experience excess mortality compared with the general
population. The group who continue to experience excess
mortality are considered to be uncured or those bound to die of
thediseaseunderstudy.Forthemodelsinthisarticleweassume
thatthesurvivaltimesofthosewhoareuncuredhaveaWeibull
distribution. We used a logit link to model the cure proportion,
whichgivesparameterestimatesthatcanbeinterpretedasodds
ratios of cure, with values greater than 1 indicating a higher
odds of cure and values less than 1 indicating a lower odds of
cure. In addition we calculated the difference, with 95%
confidence intervals, in the cure proportions.
For all cure models we applied either included terms for mode
ofdetection(screendetectedversussymptomatic)orattendance
at screening (screened within recommended interval versus
screening overdue or no smear test). We then fitted separate
models, with the following covariates also included: FIGO
stages(IA,IB,II,orIIIorhigher)andhistopathology(squamous
cellversusadenocarcinoma).Fromthemodelweexcludedthose
women with adenosquamous, small cell, neuroendocrine, or
undifferentiated carcinomas owing to small numbers. We
restricted the analysis to the younger age group when adding
stage and histopathology, because the models did not give a
good fit for the older age group—that is, the relative survival
curves did not appear to reach a plateau. To formally assess
whetheradifferenceexistedincureproportionbetweenwomen
withscreendetectedcancerandthosewithsymptomaticcancer,
weestimatedoddsratiosofcurewith95%confidenceintervals,
where the women with screen detected cancer served as the
reference group, with an odds ratio of 1. We then introduced
FIGO stage into the model to test the hypothesis that clinical
stage at detection explains any difference in cure proportion
between women with screen detected cancer and those with
symptomatic cancers. For univariate models we report the
differenceinthecureproportionwithstandarderrors,calculated
using the delta method. For the models incorporating FIGO
stage, we computed stage standardised differences in the cure
proportion by assuming that the stage distribution in the each
of the two groups was the same as that of the whole study
population. We used the same approach to estimate the
difference in cure proportions between women screened within
therecommendedintervalcomparedwiththosewhosescreening
was overdue or who had no smear test, and the hypothesis that
clinical stage at detection explains any difference in cure.
Whenpresentingestimatesofthecureproportion,wecategorise
FIGO stage in three levels (IA, IB, and II or higher), because
the estimates for further subdivisions into stages II and III or
higherwereunreliable,andconsequentlydidnotaddanyfurther
information.
Estimation of the model variables was obtained with maximum
likelihood using individual level data.
11 20 We modelled both
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RESEARCHWeibull parameters (λ and γ). (See Lambert et al
11 for further
discussion of the interpretation of estimates from cure models.)
The strsmix command in Stata was used to fit models.
21
Results
At least seven years of potential follow-up were available from
diagnosis of cervical cancer for all the women. Five years after
diagnosis, 440 out of the 1230 women had died. Among them
373 had a recorded death from cervical cancer. Thirty one
women died from other cancers, and 36 died of diagnoses not
related to cancer.
Thefiveyearrelativesurvivalforwomenatscreeningageswith
screendetectedcancerswas95%(95%confidenceinterval92%
to 97%), whereas for women with symptomatic cancers it was
69% (65% to 73%; table 1⇓). The corresponding cure
proportions were 92% (75% to 98%) and 66% (62% to 70%),
with an estimated difference in cure of 26% (15% to 36%).
However, the cure proportion for women with symptomatic
cancers presenting within the recommended screening interval
was 74% (68% to 79%), whereas for symptomatic cancers in
women overdue for screening it was 60% (53% to 66%), with
a difference in cure of 14% (6% to 23%). Differences in cure
proportions between different FIGO stages were large both for
women with screen detected cancers and for women with
symptomatic cancers (table 1). In FIGO stage IA the difference
betweenscreendetectedandsymptomaticcancerswas4%(3%
to 7%), whereas in stages IB and II or higher the difference
increased to 16% (8% to 23%) and 29% (13% to 45%),
respectively (table 1). For screen detected cancers evidence of
anysubstantialdifferenceincurewaslackingbetweensquamous
cellcarcinomaandadenocarcinoma(cureproportions93%)and
thiswasalsothecaseforsymptomaticcancers(cureproportions
67% and 66%, respectively; table 1). For both of the major
histologicalsubtypes,however,differencesincurewereapparent
between women with screen detected cancers and women with
symptomatic cancers (table 1). Deaths related to
adenosquamous,smallcell,neuroendocrine,orundifferentiated
carcinomas were too few to reliably calculate cure rates, and
no deaths occurred among women with these histological
subtypes for screen detected cancers.
Table 2⇓ presents odds ratios and differences of cure by mode
of detection and screening history. For odds ratios, the women
with interval cancers served as the reference group, with an
odds ratio of 1. The difference in cure between the women with
symptomatic cancers and those with screen detected cancers
was26%(95%confidenceinterval15%to36%;table2).When
FIGO stage was introduced into the model, the difference in
cure between the groups decreased to 15% (7% to 22%).
Thecureproportionforwomenwhohadasmeartestwithinthe
recommendedscreeningintervalatages23to65was11%(95%
confidence interval 5% to 18%) higher than for women who
were overdue or who had never had a smear test (table 3⇓).
Women with a normal smear test result had a non-significantly
lower cure proportion (difference 8%, 95% confidence interval
−0.4%to17%)thanwomenwithanabnormalsmeartestresult.
The patterns of lower cure proportions with increasing FIGO
stage was seen for both interval and overdue cases, although
the 95% confidence intervals for the stage specific differences
all included zero (table 3). The evidence for an essential
difference in relative survival or cure proportion between
squamouscellcarcinomasandadenocarcinomawasinsufficient
for interval as well as for overdue cases. Deaths in women with
the other histological subtypes were too few to make any
meaningful comparisons.
As previously done for screen detected and symptomatic
cancers, odds ratios and differences of cure were calculated for
interval and overdue cases. Compared with the interval cases,
the difference in cure for the overdue cases was 11% (95%
confidence interval 5% to 18%; table 2). In a model also
including FIGO stage, the difference in cure for overdue
compared with interval cases was statistically non-significant
(5%, −2% to 11%).
Asimilarmodelwasconstructedforhistopathologicalsubtypes,
wherenodifferenceincurecouldbediscernedbetweenwomen
with adenocarcinomas and squamous cell carcinomas (0.1%,
−8% to 8%). When adjusting for FIGO stage (IA, IB, II, and
III or higher), this result did not change notably (difference in
cure 2%, −5% to 9%).
Since age is known to be an important modifier of cervical
cancer risk and survival, all analyses were repeated, adjusting
for linear effect of age. Differences were negligible (data not
shown).
Table 4⇓ displays five year relative survival ratios, cure
proportions, and differences in cure for women over the age of
organised screening (≥66 years). In this age group the cure
proportion of women with screen detected cancers was higher
than for those with symptomatic cancers (difference in cure
36%, 95% confidence interval 11% to 80%), whereas this was
not the case for interval cases compared with overdue cases
(14%, −7% to 35%).
Figures2-4⇓⇓⇓presenttherelativesurvivalcurves,byscreening
history and mode of detection, histological type, and FIGO
stage.Womenwithscreendetectedcancerhadexcellentrelative
survival independent of previous screening history. Women
with symptomatic interval cancer had a better relative survival
at all times during follow-up than women who were
symptomatic with an overdue or absent screening test (fig 2).
Relative survival did not differ between histological types,
exceptforsmallcellneuroendocrineandundifferentiatedcancers
(fig 3). FIGO stage was a good predictor of prognosis (fig 4).
Discussion
Women with cervical cancer diagnosed as a result of a smear
test (screen detected cancers) have a better prognosis than
womenwhosecancerisdetectedonthebasisofsymptoms,and
this improvement was not attributable to lead time bias. To a
largeextenttheimprovedcurewasattributedtoscreendetected
cancers being generally found at earlier clinical FIGO stages
than symptomatic cancers.
Women with symptomatic cancer who present within the
recommendedscreeninginterval—thatis,symptomaticinterval
cancers—have better chances of cure than women with
symptomaticcancerwithanoverdueorabsentsmeartestresult.
If the screening effect on cure proportions had been due to
selective detection of harmless cancers, the more aggressive
cases would have appeared as symptomatic interval cancers
with higher mortality. On the contrary, we found that women
withsymptomaticcancershaveabetterprognosiswhencervical
cancer is diagnosed between screening intervals than when
diagnosed in women who are overdue for screening or not
screened.
If cancers were screen detected, relative survival and cure
proportion was high irrespective of whether women had
previously participated in screening, suggesting that
determinants of screening attendance have not confounded the
effect.
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RESEARCHFeeling healthy
22 and a lack of confidence in the benefits of
screening
23 24 are barriers to screening attendance for some
women, but our data imply that all women (regardless of
previous participation) can be advised that screening will
increase the likelihood of cure in case an invasive cancer is
detected.
More than three quarters of women who died from cervical
cancer had no smear test taken within the recommended
screening intervals, implying that the recommended intervals
are adequate and that further reduction of incidence and
mortality in cervical cancer should focus on reaching women
who have not attended screening.
Down-staging
In women with screen detected cancer down-staging explained
a large portion of the improved cure but not the whole
difference,comparedwithwomenwhohadsymptomaticcancer.
A plausible reason could be that our categorisation of FIGO
clinical staging of the advanced cancers was too crude to
effectively capture the whole effect of early detection by
screening. Down-staging does explain the difference in cure
betweenwomenwithintervalcancerscomparedwiththosewho
are overdue for screening or have not been screened.
Age
Half of the women who died from cervical cancer within five
years of diagnosis were over the recommended age for
screening. As few older women who continued screening died
from cervical cancer, half of the cervical cancer mortality was
in women with cancers diagnosed beyond screening ages and
whohadnothadascreeningtestformorethanfiveyears.Lethal
cervical cancers in young women before screening ages are
rare.
25 No such cases occurred in Sweden during the three years
studied. The mortality in patients younger than 30 years was so
low we were not able to study the cure proportion separately.
Histopathological type
Our results showed that the cure proportion for women with
adenocarcinomas was similar to that of women with squamous
carcinoma, also when controlling for FIGO stage, and that the
relativesurvivalofwomenwithadenosquamouscarcinomadid
not differ from these subtypes. Only women with the poorly
differentiated, small cell or neuroendocrine carcinomas had a
worse relative survival than women with the other
histopathological types.
Abnormal smears
Womenwithintervalcancersandanabnormalsmeartestresult
during the past six years had a non-significantly higher cure
proportion than women with only a normal smear test result. If
this difference is real, the reason might be that women with
abnormal smear test results are followed up to a greater extent
than women with normal smear test results.
26
Other studies
Survival studies have been carried out in other organised
programmes but most have either not distinguished between
microinvasiveandhigherstages
3ornotconsideredtheinfluence
ofopportunisticsmeartestsinthesamepopulation.
27-29Arecent
Italian study
30 included opportunistic screening. However, no
previous study has considered the possible influence of lead
time bias or the use of cure proportions to avoid this bias.
Strengths and limitations of the study
Ourauditwasdesignedtoeliminateseveralbiasessuchasthose
related to selection, testing, and recall
1 31 through prospective
follow up of all the cases in the nationwide Swedish audit,
utilising screening histories from comprehensive cytology
registers.
1 32
We have shown that cervical screening not only reduces the
risk for invasive cervical cancer
1 but is also associated with
improvedrelativesurvivalandcure.Whenevaluatingscreening
for cancer it has to be excluded if apparent improvements are
due to lead time bias, length bias, overdiagnosis, or
confounding.
8 29 A possible explanation for a seemingly better
relative survival is lead time bias—that is, when detection at an
early stage adds time to follow-up but does not alter the course
of the disease and does not prolong life. This can be a major
confounder in the evaluation of cancer screening.
8 The cure
proportion is a measure independent of lead time bias
11 and we
found significantly higher cure proportions for women with
screendetectedcancersthanforthosewithsymptomaticcancers
aswellashighercureproportionsforwomenwithsymptomatic
interval cancers compared with symptomatic overdue cancers.
The possibility of length time bias also has to be considered. If
screening picks up small indolent carcinomas but misses a
significantproportionoftherapidlygrowingaggressivetumours,
theaggressivetumourswouldappearinwomenassymptomatic
interval cancers with higher mortality.
28 29 33 34 However, the
relative survival for women with symptomatic interval cancers
was better at all times during follow-up than for women with
symptomatic cancers and an overdue or absent screening test,
and they also had a significantly higher cure proportion.
One possible explanation for the better cure of women with
screen detected cancers compared with symptomatic cancers is
confounding by “healthy volunteer bias”—that people who
participate in screening generally could be more healthy than
non-participants.Sincemostofthefemalepopulationparticipate
according to recommendations,
35 non-participants could be
considered as “unhealthy abstainers” who theoretically could
have a poor prognosis, irrespective of screening. Studies have
shown socioeconomic, cultural, and educational differences
betweenparticipantsandnon-participantstocervicalscreening,
but less so in countries with nationwide population based
programmes.
36-38 In our study the women with cancers detected
by screening had an equally excellent relative survival
irrespectiveofwhetherornottheyhadapreviousscreeningtest
taken within the recommended time, suggesting that
determinants of screening attendance were not confounders of
the effect. In addition, all Swedish residents are covered by a
common health insurance and have access to the same cancer
treatment centres. Therefore, a healthy volunteer bias or health
selection does not seem to explain our findings, although an
effect of confounding cannot be ruled out.
OurcohortcomprisedallwomenwithcervicalcancerinSweden
during three years, classified by age, clinically relevant FIGO
stage, and histopathological type, factors individually related
to screening history and to the mode of detection based on
nationwide databases. All the women in this audit have been
followed prospectively in population based registries and all
smeartests,alsooutsidethescreeningprogramme,areincluded
in the database. To our knowledge the present study is the first
to estimate cure proportion after cervical cancer.
One limitation of cure models is that they estimate a cure
proportion even when statistical cure is not reached. We have
graphicallyassessedtheappropriatenessofassumingstatistical
cure and compared estimated survival from cure models with
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RESEARCHstandardrelativesurvivalestimates.Inthecaseswherecurewas
questionable we have chosen not to present results from the
cure models. In addition we investigated relative survival by
age group using Finnish and Swedish cancer registry data to
assess whether a plateau in the relative survival function was
observed. If excess mortality occurred after 10 years then the
modelswouldbeestimatingsomethingcloseto10yearrelative
survivalratherthanthecureproportion.Thedefinitionofscreen
detected and symptomatic cancer is based on interpretation of
timing of smear tests in relation to diagnosis of cancer and it is
possiblethatasmallnumberofwomenwithsymptomaticcancer
and slow investigations could have been classified as having
screen detected cancers.
Conclusions
Detection of invasive cancer by cervical screening implies a
favourable prognosis compared with cancer being detected on
the basis of symptoms. The effect was stronger than what is
reflected in down-staging and was not attributable to lead time
bias. Also, women with symptomatic interval cancers had a
better prognosis than women with symptomatic cancers who
did not have a smear test within the recommended screening
interval. The effect on cervical cancer cure should be included
when evaluating cervical screening programmes.
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RESEARCHWhat is already known on this topic
Women with cervical cancers detected by screening have an improved survival
However, evaluations of the benefit of screening programmes can be distorted by lead time bias
What this study adds
Cervical cancer screening is associated with improved cure
The effect is not attributable to lead time bias and is larger than what is reflected in earlier stage diagnosis (down-staging)
Evaluations of screening programmes should consider the assessment of cure proportions
Tables
Table 1| Five year relative survival ratios and cure proportions of cervical cancer for women age 23-65, by mode of detection, clinical stage,
and histopathology
Difference
in cure
(95% CI)
Symptomatic cancers Screen detected cancers
Variables
Cure
proportion
(95% CI)
5 year
relative
survival
(95% CI)
Deaths
during
observation
period
Cancer
specific
death at
five
years
No of
cases
Cure
proportion
(95% CI)
5 year
relative
survival
(95% CI)
Deaths
during
observation
period
Cancer
specific
death at
five
years
No of
cases
26 (15 to
36)
66 (62 to 70) 69 (65 to 73) 199 166 567 92 (75 to
98)
95 (92 to 97) 22 11 273 All cases
Latest screening
interval:
14 (6 to
23)†
74 (68 to 79) 75 (69 to 80) 72 65 256 —* 95 (90 to 98) 15 6 153 Interval cases
60 (53 to 66) 65 (60 to 70) 127 101 311 95 (87 to
98)
96 (90 to 98) 7 5 120 Overdue cases
FIGO stage:
4 (3 to 7) 94 (88 to 97) 94 (86 to 97) 7 5 99 98 (96 to
99)
98 (93 to
100)
5 2 137 IA
(microinvasive)
16 (8 to 23) 75 (68 to 81) 81 (76 to 85) 71 51 280 91 (83 to
95)
97 (92 to
100)
10 3 117 IB (localised)
29 (13 to
45)
37 (30 to 44) 40 (32 to 47) 121 110 188 65 (48 to
80)
64 (38 to 81) 7 6 19 II or higher
(advanced)
Histopathology:
26 (20 to
33)
67 (61 to 72) 71 (66 to 75) 143 115 412 93 (86 to
96)
97 (93 to 99) 14 6 203 Squamous cell
carcinoma
27 (18 to
35)
66 (57 to 74) 68 (59 to 76) 41 37 121 93 (86 to
96)
90 (79 to 96) 8 5 65 Adenocarcinoma
— — 73 (46 to 88) 5 5 18 — >100 0 0 3 Adenosquamous
carcinoma
— — 44 (20 to 66) 10 9 16 — >100 0 0 2 Small cell
carcinoma
*Estimate could not be calculated reliably owing to poor fitting cure model.
†Interval and overdue symptomatic cancer cases compared.
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RESEARCHTable 2| Odds ratios and differences in cure from cervical cancer on women aged 23-65, by mode of detection and previous screening
history
Difference in cure (95% CI) Odds ratio (95% CI)
Variables Adjusted for FIGO stage* Unadjusted Adjusted for FIGO stage Unadjusted
Mode of detection:
15 (7 to 22) 26 (15 to 36) 1.00 1.00 Screen detected (reference)
0.31 (0.16 to 0.62) 0.17 (0.05 to 0.65) Symptomatic
Previous screening history:
5 (−2 to 11) 11 (5 to 18) 1·00 1·00 Screened (reference)
0.72 (0.46 to 1.12) 0.55 (0.38 to 0.79) Screening overdue or no smear
*Stage standardised difference.
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RESEARCHTable 3| Five year relative survival ratios and cure proportions of cervical cancer for women age 23-65 by previous screening history,
clinical stage, and histopathology
Difference
in cure
(95% CI)
Screening overdue or no smear test Screened within recommended interval
Variables
Cure
proportion
(95% CI)
5 year
relative
survival
(95% CI)
Deaths
during
observation
period
Cancer
specific
death at
five
years
No of
cases
Cure
proportion
(95% CI)
5 year
relative
survival(95%
CI)
Deaths
during
observation
period
Cancer
specific
death at
five
years
No of
cases
11 (5 to 18) 70 (65 to
74)
74 (69 to 78) 134 106 431 81 (76 to 85) 82 (78 to 86) 87 71 409 All cases
Latest screening
interval:
8 (−0.4 to
17)
— — — — — 78 (72 to 83) 80 (74 to 84) 66 57 278 Normal smear
test result
— — — — — 86 (78 to 92) 88 (81 to 93) 21 14 131 Abnormal smear
test result
FIGO stage:
1 (−0.4 to 3) 96 (91 to
98)
95 (89 to 98) 6 5 110 97 (94 to 99) 97 (92 to 99) 6 2 126 IA
(microinvasive)
7 (−1 to 15) 74 (63 to
83)*
86 (80 to 90) 39 23 186 82 (75 to 87) 86 (80 to 90) 42 31 211 IB (localised)
10 (−0.6 to
21)
35 (28 to
44)
39 (31 to 47) 89 78 135 46 (36 to 56) 47 (35 to 58) 39 38 72 II or higher
(advanced)
Histopathology:
10 (3 to 17) 71 (65 to
76)
74 (69 to 78) 107 84 343 81 (75 to 86) 86 (81 to 90) 50 37 272 Squamous cell
carcinoma
10 (3 to 18) 69 (59 to
77)*
75 (63 to 84) 18 14 67 79 (72 to
85)*
76 (67 to 83) 31 28 119 Adenocarcinoma
— 60 (25 to 83) 4 4 10 — 92 (52 to 100) 1 1 11 Adenosquamous
carcinoma
— 64 (30 to 85) 5 4 11 — 29 (4 to 63) 5 5 7 Small cell
carcinoma
*Estimate could not be calculated reliably owing to poor fitting cure model.
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RESEARCHTable 4| Five year relative survival ratios and cure proportions of cervical cancer for women age 66 or older by mode of detection and
previous screening history
Difference in cure
(95% CI)
Cure proportion (95%
CI)
5 year relative survival
(95% CI)
Deaths during
observation period
Cancer specific
death at five years No of cases Variables
Mode of detection:
36 (11 to 80) 76 (46 to 92) 77 (48 to 97) 11 5 23 Screen detected cancers
40 (33 to 47) 44 (38 to 50) 278 191 367 Symptomatic cancers
Screening history:
14 (−7 to 35) 54 (35 to 72) 56 (35 to 74) 19 12 32 Screened within recommended
interval
40 (32 to 48) 45 (38 to 51) 270 184 358 Screening overdue or no
smear test
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RESEARCHFigures
Fig 1 Definition of mode of detection and screening history based on time since latest smear test.* Result of smear tests
taken without clinical suspicion do not lead to diagnosis of invasive cancer in less than one month. †Smear tests taken less
than six months before diagnosis cannot have prevented invasive cancer but are considered, after referral and biopsy, to
lead to diagnosis of a prevalent cancer
Fig 2 Relative survival ratios of cervical cancer (all histological types) for women of all ages, by screening history and mode
of detection
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RESEARCHFig 3 Relative survival ratios of cervical cancer for women of all ages, by histological type
Fig 4 Relative survival ratios of cervical cancer (all histological types) for women of all ages, by FIGO stage
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